Special Issue "Molecular Role of PARP in Health and Disease 2020"

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Nuclei: Function, Transport and Receptors".

Deadline for manuscript submissions: 31 December 2020.

Special Issue Editors

Prof. Dr. Péter Bay
Website SciProfiles
Guest Editor
Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, H-4032, Hungary
Interests: poly(ADP-ribose)polymerase; PARP; mitochondria; sirtuin; metabolism
Special Issues and Collections in MDPI journals
Dr. Tibor Pankotai
Website SciProfiles
Guest Editor
Department of Oral Biology and Experimental Dental Research, Faculty of Dentistry, University of Szeged, Tisza Lajos krt 83, H-6722 Szeged, Hungary
Interests: PARP; DNA repair; transcription

Special Issue Information

Dear Colleagues,

Poly(ADP-ribose) polymerases (PARPs or ARTDs) represent a 17-member family characterized by a common catalytic subunit. PARPs use NAD+ as a substrate and PARP1 or PARP2, when activated, can limit NAD+ availability in cells to other enzymes. PARPs and their product, poly(ADP-ribose), regulate transcription and chromatin structure. PARP enzymes have a crucial role in regulating DNA repair making major PARP enzymes attractive targets for pharmacological inhibition. In the past few years, PARP inhibitors have entered clinical use, while at the same time, more specific PARP inhibitors are being developed to target only tankyrases or mono-ADP-ribose polymerases among the PARP family members. In addition to DNA repair and oncological transformation, PARPs influence a plethora of other cellular (patho)physiological processes from metabolism to virus–host interactions.

Prof. Dr. Péter Bay
Dr. Tibor Pankotai
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.ynsqex.icu by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PARP
  • ARTD
  • PARP inhibitors
  • PARylation
  • MARylation
  • macrodomain
  • olaparib
  • rucaparib
  • niraparib chromatin
  • transcription
  • protein degradation postrranslational modifications
  • DNA repair
  • cell division
  • hetarochromatin tumor
  • neoplasia
  • cytostatic treatment
  • synthetic lethality
  • enzyme trapping
  • mitochondria
  • cell death
  • oxidative stress inflammation
  • viral infection
  • energy sensors
  • circadian rhtythm
  • metabolic diseases
  • aging

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas
Cells 2020, 9(5), 1135; https://doi.org/10.3390/cells9051135 - 05 May 2020
Abstract
Introduction: Mucosal melanoma is rare and associated with poorer prognosis in comparison to conventional melanoma subtypes. Little is known about the prognostic significance as well as possible associations between PARP1 and immunologic response in mucosal melanoma. Methods: PARP1, PD-L1 and IDO1 immunostains were [...] Read more.
Introduction: Mucosal melanoma is rare and associated with poorer prognosis in comparison to conventional melanoma subtypes. Little is known about the prognostic significance as well as possible associations between PARP1 and immunologic response in mucosal melanoma. Methods: PARP1, PD-L1 and IDO1 immunostains were performed on 192 mucosal melanomas including 86 vulvar, 89 sinonasal, and 17 anorectal melanomas. Results: By Kaplan–Meier analyses, high PARP1 expression correlated with worse overall and melanoma-specific survival (log-rank p values = 0.026 and 0.047, respectively). Tumors with combined PARP1 and IDO1 high expression correlated with worse overall and melanoma-specific survival (p = 0.015, 0.0034 respectively). By multivariate analyses, high PARP1 expression remained a predictor of worse survival independent of stage. By Fisher’s exact test, high PARP1 expression correlated with highly mitogenic tumors (p = 0.02). High tumoral PD-L1 and IDO1 expression were associated with ulcerated primary tumors (p = 0.019, 0.0019, respectively). By linear regression analyses, correlations between PARP1 expression versus IDO1 expression (p = 0.0001) and mitotic index (p = 0.0052) were observed. Conclusion: Increased expression of PARP1 is an independent negative prognostic marker in mucosal melanomas. The association between PARP1 and IDO1 and their combined adverse prognostic role raise the potential of combined therapy in mucosal melanoma. Full article
(This article belongs to the Special Issue Molecular Role of PARP in Health and Disease 2020)
Show Figures

Figure 1

Review

Jump to: Research

Open AccessFeature PaperReview
Emerging Roles of Post-Translational Modifications in Nucleotide Excision Repair
Cells 2020, 9(6), 1466; https://doi.org/10.3390/cells9061466 - 15 Jun 2020
Abstract
Nucleotide excision repair (NER) is a versatile DNA repair pathway which can be activated in response to a broad spectrum of UV-induced DNA damage, such as bulky adducts, including cyclobutane-pyrimidine dimers (CPDs) and 6–4 photoproducts (6–4PPs). Based on the genomic position of the [...] Read more.
Nucleotide excision repair (NER) is a versatile DNA repair pathway which can be activated in response to a broad spectrum of UV-induced DNA damage, such as bulky adducts, including cyclobutane-pyrimidine dimers (CPDs) and 6–4 photoproducts (6–4PPs). Based on the genomic position of the lesion, two sub-pathways can be defined: (I) global genomic NER (GG-NER), involved in the ablation of damage throughout the whole genome regardless of the transcription activity of the damaged DNA locus, and (II) transcription-coupled NER (TC-NER), activated at DNA regions where RNAPII-mediated transcription takes place. These processes are tightly regulated by coordinated mechanisms, including post-translational modifications (PTMs). The fine-tuning modulation of the balance between the proteins, responsible for PTMs, is essential to maintain genome integrity and to prevent tumorigenesis. In this review, apart from the other substantial PTMs (SUMOylation, PARylation) related to NER, we principally focus on reversible ubiquitylation, which involves E3 ubiquitin ligase and deubiquitylase (DUB) enzymes responsible for the spatiotemporally precise regulation of NER. Full article
(This article belongs to the Special Issue Molecular Role of PARP in Health and Disease 2020)
Show Figures

Figure 1

Back to TopTop 宝马游戏手机网站 短期投资理财 北京pk赛车预测号码 云南十一选五任六遗漏 体彩大乐透中奖规则 江西水泥股票行情 pk10赛车历史开奖直播 河南十一选五走势图官网 新手怎样理财收益最大 贵州快3号码统计图 王中王心水王中王资料 上海11选5前三直 贵州十一选五分布走势一定牛 群英会技巧和方法 北京快3是不是官方的 最新最全黑尤冮体彩6十1 双色球怎样投注划算